Investment Rating - The report assigns a "Buy" rating to the company with a target price of 23.65 CNY, compared to the current price of 15.11 CNY [5][10][42]. Core Insights - The demand for innovative drug development is recovering, coupled with growth in overseas business, driving profitability recovery for the company, indicating a new growth cycle [2][10]. - The company is expected to achieve revenue of 7.93 billion CNY in 2025, representing a year-on-year growth of 15.5%, with a net profit of 1.44 billion CNY, reflecting a growth of 31.5% [10][15][42]. - The core business structure is optimized, with high-end models and pharmacodynamic services driving growth, accounting for over 90% of total revenue [17][22]. Financial Summary - Total revenue is projected to grow from 622 million CNY in 2023 to 1.099 billion CNY in 2027, with annual growth rates of 20.5%, 10.4%, 15.5%, 17.7%, and 17.6% respectively [4][11]. - Net profit attributable to the parent company is expected to fluctuate, with estimates of 159 million CNY in 2023, dropping to 110 million CNY in 2024, and then recovering to 205 million CNY by 2027 [4][11]. - Earnings per share (EPS) is projected to increase from 0.39 CNY in 2023 to 0.50 CNY in 2027 [4][11]. Business Analysis - The core business includes commercialized mouse models, pharmacodynamic services, and custom breeding, which collectively drive significant revenue growth [17][27]. - The commercialized mouse model segment is the cornerstone of the business, with revenue growth supported by an increase in high-end product sales and operational efficiency improvements [22][27]. - The pharmacodynamic service segment is expected to become a key revenue growth engine, benefiting from increased demand for drug testing and model services [25][38]. Overseas Business Growth - The company has seen significant growth in overseas revenue, reaching 1.07 billion CNY in the first three quarters of 2025, a year-on-year increase of 23.62% [29][32]. - The establishment of a new headquarters in San Diego enhances local service capabilities, which is expected to drive further revenue growth [29][32]. - The company is also developing a humanized antibody discovery platform, which is anticipated to contribute to future growth [33][34]. Profitability Forecast and Investment Recommendations - The company is projected to achieve revenues of 9.34 billion CNY and 10.99 billion CNY in 2026 and 2027, respectively, with corresponding net profits of 1.74 billion CNY and 2.05 billion CNY [42]. - The report suggests that the company’s strong technical advantages in commercialized mouse models and pharmacodynamic services, along with ongoing overseas expansion, will enhance profitability [10][42]. - A valuation based on comparable companies suggests a target price of 23.65 CNY, reflecting a 55 times PE ratio for 2026 [10][40][42].

Investment Rating - The report assigns an "Accumulate" rating to the company with a target price of 23.65 CNY, compared to the current price of 15.11 CNY [5][10][42]. Core Insights - The demand for innovative drug development is recovering, coupled with growth in overseas business, driving profitability recovery for the company, indicating a new growth cycle [2][10]. - The company is expected to achieve revenue of 7.93 billion CNY in 2025, representing a year-on-year growth of 15.5%, with a net profit of 1.44 billion CNY, reflecting a growth of 31.5% [10][15][42]. - The core business structure is optimized, with high-end models and pharmacodynamic services driving growth, accounting for over 90% of total revenue [17][22]. Financial Summary - Total revenue is projected to grow from 622 million CNY in 2023 to 1.099 billion CNY in 2027, with a compound annual growth rate (CAGR) of 17.6% [4][39]. - Net profit attributable to the parent company is expected to increase from 159 million CNY in 2023 to 205 million CNY in 2027, with a significant growth of 31.5% in 2025 [4][42]. - Earnings per share (EPS) is forecasted to rise from 0.39 CNY in 2023 to 0.50 CNY in 2027 [4][42]. Business Analysis - The core business includes commercialized mouse models, pharmacodynamic services, and custom breeding, which collectively drive revenue growth [17][27]. - The commercialized mouse model business is the cornerstone, with revenue growth supported by an increase in high-end product sales and improved gross margins [22][25]. - The pharmacodynamic service segment is expected to become a significant growth engine, benefiting from increased demand for drug testing and model services [25][38]. Overseas Business Growth - The company reported overseas revenue of 1.07 billion CNY in the first three quarters of 2025, marking a year-on-year increase of 23.62%, with a notable 63.97% growth in Q3 [29][32]. - The establishment of a new headquarters in San Diego enhances local service capabilities, which is expected to drive future revenue growth [29][32]. - The company is also developing a humanized antibody discovery platform, which is anticipated to contribute to long-term growth potential [33][34]. Profitability Forecast and Investment Recommendations - Revenue is projected to grow steadily, with expectations of 9.34 billion CNY in 2026 and 10.99 billion CNY in 2027, maintaining a growth rate of 17.7% and 17.6% respectively [42]. - The report suggests that the company’s strong technical advantages in commercialized mouse models and pharmacodynamic services will enhance profitability over time [10][42]. - Based on comparable company valuations, a price-to-earnings (PE) ratio of 55 times for 2026 is recommended, leading to a target price of 23.65 CNY [10][40][42].

Core Insights - The company reported a revenue of 687 million yuan for 2024, representing a year-over-year increase of 10.39%, but the net profit attributable to shareholders decreased by 30.89% to 110 million yuan [1] - For Q1 2025, the company achieved a revenue of 171 million yuan, up 8.76% year-over-year, with a net profit of 30 million yuan, reflecting a slight increase of 1.7% [1] Revenue Breakdown - The revenue from the commercialization of mouse models was 400 million yuan, up 9.0% year-over-year; functional efficacy revenue was 150 million yuan, up 14.6%; custom breeding revenue was 85 million yuan, up 8.0%; and model customization revenue was 34 million yuan, down 3.4% [2] - The overall gross margin for the main business in 2024 was 62.0%, a decrease of 5.6 percentage points from 2023 [2] Regional Performance - Domestic revenue reached 572 million yuan in 2024, with a gross margin of 59.4%, reflecting an 8.3% year-over-year increase [3] - The company expanded its overseas market, generating 114 million yuan in revenue, a 22.5% year-over-year increase, with a gross margin of 75.3%, outperforming domestic business [3] - The overall sales expense ratio increased by 2.39 percentage points to 15.60%, impacting net profit, although the sales net profit margin improved in Q1 2025 to 17.55%, up 1.56 percentage points from 2024 [3] Global Capacity Planning - By the end of 2024, the company had seven major bases in China with a total capacity of approximately 280,000 cages, achieving full coverage [4] - New production capacity of 80,000 cages in Shanghai, Beijing, and Guangdong was nearly fully utilized [4] - The company plans to enhance its overseas presence by seeking suitable areas in Europe for animal facility leasing, in addition to its existing facility in San Diego, USA [4] - The company has established sales in over 20 countries and collaborated with eight of the top ten global pharmaceutical companies, while also adding over 200 research users and 600 industrial clients domestically, and 80 research users and 90 industrial clients overseas [4] Profit Forecast and Valuation - Due to weak global biopharmaceutical R&D investment and increased overseas expenditures, the EPS forecasts for 2025 and 2026 have been revised down to 0.34 yuan and 0.40 yuan, respectively, representing reductions of 48% and 50% [4] - An additional EPS forecast for 2027 is set at 0.47 yuan, with corresponding PE ratios of 33, 28, and 24 for 2025-2027 [4] - Given the significant stock price correction and the current low valuation, along with steady progress in overseas business, the company maintains a "buy" rating [4]

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company is experiencing short-term profit pressure, but its overseas business continues to maintain high growth [7] - Revenue for 2024 is projected at 6.87 billion yuan, reflecting a year-on-year growth of 10.39%, while net profit is expected to decline by 30.89% to 1.10 billion yuan [7] - The company has a strong growth potential due to its comprehensive mouse model offerings and successful overseas market expansion [7] Financial Summary - Total revenue forecast for 2023A is 622.19 million yuan, with a projected increase to 686.84 million yuan in 2024A and 814.88 million yuan in 2025E, representing growth rates of 20.45%, 10.39%, and 18.64% respectively [1] - The net profit for 2023A is 158.91 million yuan, expected to decrease to 109.82 million yuan in 2024A, but is projected to recover to 132.74 million yuan in 2025E [1] - The latest diluted EPS is forecasted to be 0.39 yuan for 2023A, decreasing to 0.27 yuan in 2024A, and then gradually increasing to 0.48 yuan by 2027E [1] Business Performance - The company achieved a revenue of 4.0 billion yuan from commercialized mouse models in FY24, with a growth of 9.0%, and 1.5 billion yuan from functional efficacy, growing by 14.6% [7] - Overseas revenue reached 1.14 billion yuan, marking a 22.5% increase, while domestic revenue was 5.72 billion yuan, up by 8.3% [7] - The gross profit margin for 2024 is reported at 61.99%, a decrease of 5.62 percentage points compared to the previous year [7] Growth Drivers - The company has completed its domestic facility layout with approximately 280,000 cages, which is expected to enhance profitability as it transitions to gene-edited mouse business [7] - The overseas market is anticipated to continue its high growth trajectory, supported by a skilled engineering workforce and newly established production capacity [7] - The company is actively expanding its product offerings, including wild-type mice and humanized antibody transgenic models, to capture additional market demand [7]